Ruben A. Mesa, MD, provides an update on the COMFORT-1 trial, which found that ruxolitinib has durable efficacy and long-term safety in patients with myelofibrosis.
COMFORT: Five-Year Outcomes of Ruxolitinib in Patients With Myelofibrosis
Recent Articles
Coagulation Conundrums: Managing Hemostatic and Thrombotic Complications in Young Women
In a case-based discussion as part of this year’s Education Program, Andra James, MD, MPH, and Margaret Ragni, MD, MPH, will answer challenging questions...
ASH-a-Palooza Redux
The 2018 ASH Annual Meeting in San Diego marked the debut of ASH-a-Palooza, the reimagined Trainee Day. This new educational experience offers a relaxed,...
How To Give a Talk
In this special edition of “How We Teach,” Mikkael Sekeres, MD, MS, and Joseph Mikhael, MD, MEd, offer advice to new – and experienced –...
Foreign Scientists With Ties to China May Be Stealing U.S. Research
The National Institutes of Health (NIH) and the FBI have launched an investigation into foreign scientists who are allegedly stealing biomedical research from institutions...
Will the FDA’s Suggestions Help Curb Drug Shortages?
Drug shortages, especially of older and less expensive medications, are increasing, causing hospitals to ration lifesaving treatments. According to a report released in late...
Current Issue
November 2019, Volume 5, Issue 13
This issue features explores treating older patients with frailty, discusses the management of primary mediastinal B-cell lymphoma, and more.
